Crizanlizumab Dosage and Route of Administration
Crizanlizumab is administered intravenously at 5 mg/kg over 30 minutes, with the first two doses given 2 weeks apart, followed by monthly dosing every 4 weeks thereafter. 1
Dosing Regimen
The FDA-approved dosing schedule for crizanlizumab (ADAKVEO) is straightforward:
- Loading phase: 5 mg/kg IV at Week 0 and Week 2
- Maintenance phase: 5 mg/kg IV every 4 weeks (monthly) starting at Week 6 1
The medication is supplied as 100 mg/10 mL single-dose vials and must be diluted prior to administration. The infusion should be delivered over 30 minutes via intravenous route 1.
Patient Population
Crizanlizumab is FDA-approved for patients aged 16 years and older with sickle cell disease to reduce the frequency of vaso-occlusive crises. 1 The SUSTAIN trial, which supported FDA approval, demonstrated a 45.3% reduction in median annual rate of pain crises compared to placebo (1.63 vs 2.98 crises per year, P=0.01) 2.
Important Considerations:
- Pediatric patients under 16 years: Safety and efficacy have not been established 1
- Weight-based dosing: The 5 mg/kg dose applies to both adults and adolescents ≥16 years
- Concomitant therapy: Can be used with or without hydroxyurea/hydroxycarbamide 2
Administration Details
The infusion protocol requires:
- Infusion time: 30 minutes
- Route: Intravenous only
- Preparation: Must be diluted before administration (supplied as concentrate)
- Monitoring: Patients should be observed during and after infusion for infusion-related reactions 1
Dosing Alternatives Studied
While a 7.5 mg/kg dose was evaluated in clinical trials, the FDA-approved dose remains 5 mg/kg 1. The STAND trial evaluated both 5.0 mg/kg and 7.5 mg/kg doses but found no significant efficacy difference between doses or versus placebo in the primary analysis, though this was confounded by multiple factors including the COVID-19 pandemic 3. The SOLACE-adults study showed both doses achieved sustained P-selectin inhibition with similar safety profiles 4.
Clinical Context
Crizanlizumab represents the first P-selectin blocker approved for sickle cell disease, working by preventing multicellular adhesion between endothelial cells, platelets, red blood cells, and leukocytes 1. The 2024 AHA/ASA stroke prevention guidelines acknowledge that the role of newer therapies including crizanlizumab in stroke prevention warrants further investigation 5.
Infusion-Related Reactions
Clinicians should be aware that severe infusion-related reactions can occur, characterized by severe pain within 24 hours of infusion. Management strategies should be individualized based on prior history of reactions, with consideration for premedication, infusion rate adjustments, and close monitoring 6.
The terminal half-life is approximately 10.6 days, supporting the monthly dosing interval 1. No dose adjustments are specified for renal or hepatic impairment, though pharmacokinetic data in these populations is limited 1.